Blumberg scientists earn state grants for COVID-19 R&D >>click here>>

Jai Mei, MD, PhD Adjunct Professor

Jai Mei, MD, PhD

Adjunct Professor of Experimental Therapeutics

Education

Ph.D., Pharmacology & Toxicology (1993), University of Maryland, Baltimore, Maryland

M.D., (1989), Exchange Medical Program Sponsored by Yale-China Association, New Haven, CT, Xiang-Ya (Yale) Medical College, Hunan, China

 

Industrial Experience

Dr. Mei founded Antengene Corporation in Apr 2017. Antengene currently has 6 clinical stage and 6 pre-clinical stage assets respectively in its pipeline. Since establishment, Antengene has completed two rounds of financing with Series A of USD 21 million (Aug. 2017) and Series B of USD 120 million (Jan. 2019). Currently, Antengene is conducting ten clinical trials in China and other APAC countries/regions, including two registration trials. The first commercial launch of Antengene’s lead pipeline product in APAC is expected in 2021. Antengene has entered into strategic partnership with Celgene (now BMS), AstraZeneca and Karyopharm Therapeutics over the past two years.

Prior to founding Antengene, Dr. Mei previously served as the Global Clinical Lead of Clinical Development at Celgene Corporation. Dr. Mei has over 25 years of experience in the clinical development of oncology therapeutics globally and successfully led the development of multiple oncology products, including REVLIMID® in China. REVLIMID® received NDA approval in China and launched in 2013. Outside of the China market, Dr. Mei was the clinical leader for the development of REVLIMID®, POMALYST®, IDHIFA®, etc., in more than 30 countries.

Before his role at Celgene, Dr. Mei served in multiple clinical development positions at Novartis Oncology as Global Clinical Program Head and at J&J Pharmaceutical Research & Development as early clinical development leader. Dr. Mei completed eight years of cancer and clinical research at the U.S. National Cancer Institute (NCI). Dr. Mei has also been the author of over 70 publications and holds multiple patents.

Current Position: Founder, Chairman & CEO of Antengene Corporation

 

Research and Experience

Over 25 years of oncology research, discovery, and early to late stage clinical drug development experience within the pharmaceutical industry, clinical practice, and academia in key international leadership positions such as Global Therapeutic Head and Executive Director.

 

Publications and Patents

Author/co-author of 92 publications, including manuscripts and abstracts. Named as inventor/co-inventor of 7 issued U.S. Patents and has presented over 14 invited lectures at National and International meetings.


Awards

2010  Celgene Recognition for Dedicated Service.

2006  Johnson & Johnson Pharmaceutical Research and Development Vision Award for Successfully Completing a Special Clinical Study Assignment.

2005  Johnson & Johnson Pharmaceutical Research and Development Vision Award for Significant Contribution to Due Diligence/Business Development Project.

2003  Johnson & Johnson Pharmaceutical Research and Development Vision Award for Leadership Role and Outstanding Performance/Contribution to a NME.

2000  National Cancer Institute On the Spot Cash Award for Exemplary Professional Performance.

← Back to In-House Adjunct